Tianjin Lisheng Pharmaceutical Co Ltd

Tianjin Lisheng Pharmaceutical Co Ltd maintains a strong liquidity position, with a current ratio of 4.37, indicating the company can easily cover its short-term liabilities with its short-term assets. The company's liquidity_fpt score suggests a medium liquidity risk, which is consistent with its financial structure and cash flow generation. The company's free cash flow of 367,031,760 CNY supports its operational flexibility and capacity to fund future growth or return capital to shareholders.

In terms of profitability, the company's return on equity (ROE) of 8.99% and return on assets (ROA) of 7.45% are strong indicators of efficient capital utilization and asset management. These metrics suggest that the company is generating solid returns relative to its equity and total assets. The gross profit margin of 54.1% and operating margin of 33.7% further support the company's profitability, indicating a healthy margin structure compared to industry norms.

The company's revenue is primarily concentrated in its domestic market, with no significant international operations disclosed in the available data. This suggests a high degree of geographic concentration, which could expose the company to regional economic and regulatory risks. The company operates in a single business segment, which simplifies its operations but also limits diversification benefits.

Looking at the company's growth trajectory, the outlook for the current fiscal year is positive, with revenue expected to grow by a modest amount. The company's capital expenditure of -37,459,300 CNY indicates a reduction in investment in physical assets, which may reflect a shift in strategic focus or a response to market conditions. The company's net income of 416,283,340 CNY and operating income of 469,076,760 CNY suggest a stable and profitable business model.

The company's risk profile is characterized by a low dilution potential, with no significant dilution sources identified in the available data. The company's debt-to-equity ratio of 0.02 is very low, indicating a conservative capital structure with minimal reliance on debt financing. However, the company's net cash position is negative after subtracting total debt, which could be a concern if cash flow generation is disrupted.

Recent events and filings do not indicate any material changes in the company's operations or financial position. The company's latest actual EPS of 0.73 CNY and actual revenue of 733,084,000 CNY align with its reported financial performance, suggesting transparency and consistency in its reporting.

Tianjin Lisheng Pharmaceutical Co Ltd (002393.SZ) has undergone a formal classification update, with its economic sector now explicitly identified as Healthcare and its primary activity defined as Pharmaceuticals & Medical Research. This structural clarification provides a clearer framework for analyzing the company’s operational focus within the broader medical industry landscape. Concurrently, the firm’s risk profile has been initialized with specific assessments. Dilution risk is currently rated as low, suggesting that existing shareholders face minimal immediate threat from equity expansion. This assessment offers a baseline for evaluating capital structure stability in the absence of recent dilutive events. Liquidity risk, however, is classified as medium, indicating potential constraints or variability in the company’s ability to meet short-term obligations or trade efficiently. This rating highlights an area of operational or market friction that investors may need to monitor, particularly given the lack of analyst coverage or index membership data to provide external validation of trading dynamics. The company currently reports zero officers, analysts, index memberships, and top holders in the available dataset. This absence of detailed stakeholder or governance metrics limits the depth of fundamental analysis, making the newly established sector and risk classifications the primary available signals for assessing Tianjin Lisheng Pharmaceutical’s current standing.